Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster

Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster

The global coronavirus disease 2019 (COVID-19) pandemic was caused by SARS-CoV-2. The authors developed an mRNA vaccine (LVRNA009) that encoded the S protein of the Wuhan-Hu-1 strain and evaluated the long-term protection potential against SARS-CoV-2 variants. Mice were initially vaccinated with 2 d...

Full description

Saved in:

Bibliographic Details
Main Authors:	Jun Liu, Jing Sun, Liping Luo, Yanhong Tang, Hu Guo, Yiyun He, Qi Liu, Xuya Yu, Yumei Huang, Siyuan Zhang, Airu Zhu, Jun Dai, Fan Zhang, Tao Huang, Jincun Zhao, Yucai Peng
Format:	Article
Language:	English
Published:	Compuscript Ltd 2024-04-01
Series:	Zoonoses
Online Access:	https://www.scienceopen.com/hosted-document?doi=10.15212/ZOONOSES-2023-0060
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Corrigendum to: Long-Term Protection from SARS-CoV-2 Variants in Mice by a Phase II Clinically Evaluated Original mRNA Vaccine Booster
by: Jun Liu, et al.
Published: (2025-02-01)

Neutralizing antibody responses to SARS-CoV-2 variants after COVID-19 vaccination and boosters
by: Kabita Adhikari, et al.
Published: (2025-06-01)

An omicron-based vaccine booster elicits potent neutralizing antibodies against emerging SARS-CoV-2 variants in adults
by: Tao Li, et al.
Published: (2023-12-01)

Functional antibody responses to SARS-CoV-2 variants before and after booster vaccination among adults in Ghana
by: F. D. Partey, et al.
Published: (2025-07-01)

Booster vaccination against the SARS-CoV-2: mechanisms and efficiency
by: S. A. Berns, et al.
Published: (2023-12-01)

SARS-CoV-2 vaccine boosters: The time to act is now.
by: Maya Petersen, et al.
Published: (2021-12-01)

Protection efficacy of mRNA-based SARS-CoV-2 variant vaccine in non-human primates
by: Dongrong Yi, et al.
Published: (2025-02-01)

In vivo determination of protective antibody thresholds for SARS-CoV-2 variants using mouse models
by: Peilan Wei, et al.
Published: (2025-12-01)

Circulating Antibodies Against Common Cold Coronaviruses Do Not Interfere with Immune Responses to Primary or Booster SARS-CoV-2 mRNA Vaccines
by: Bindu Adhikari, et al.
Published: (2025-05-01)

Clinical characteristics and booster vaccine effectiveness of the Omicron variant
by: Lijun Sun, et al.
Published: (2024-11-01)

Effective cellular and neutralizing immunity against SARS-CoV-2 after mRNA booster vaccination is associated with pDC and B cell activation
by: Dorit Fabricius, et al.
Published: (2025-05-01)

Comparable immune escape capacity between KP.2 and other SARS-CoV-2 variants in the central Chinese population after the first COVID-19 booster
by: Youhua Yuan, et al.
Published: (2025-05-01)

mRNA vaccines with RBD mutations have broad-spectrum activity against SARS-CoV-2 variants in mice
by: Xiaoming Liang, et al.
Published: (2025-01-01)

Neutralizing antibody titers over 12 months after SARS-CoV-2 mRNA vaccine booster in patients with relapsing multiple sclerosis continuously treated with ofatumumab
by: Tjalf Ziemssen, et al.
Published: (2024-12-01)

Intranasal booster induces durable mucosal immunity against SARS-CoV-2 in mice
by: Reshma Koolaparambil Mukesh, et al.
Published: (2025-07-01)

Safety and immunogenicity of an mRNA-1273 vaccine booster in adolescents
by: Amparo L. Figueroa, et al.
Published: (2025-12-01)

Immune Response to Initial and Booster SARS-CoV-2 mRNA Vaccination in Patients Treated with Siponimod—Final Analysis of a Nonrandomized Controlled Clinical Trial (AMA-VACC)
by: Tjalf Ziemssen, et al.
Published: (2023-08-01)

The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern.
by: Carl Graham, et al.
Published: (2022-10-01)

Neutralizing antibody test supports booster strategy for young individuals after SARS-CoV-2 Omicron breakthrough
by: Yichuan Yao, et al.
Published: (2025-01-01)

Evolution of SARS-CoV-2 T cell responses as a function of multiple COVID-19 boosters
by: Ricardo da Silva Antunes, et al.
Published: (2025-07-01)

Effect of XBB.1.5-adapted booster vaccination on the imprinting of SARS-CoV-2 immunity
by: Jernej Pušnik, et al.
Published: (2024-11-01)

Seroprevalence against SARS-CoV-2 after booster vaccination in a prison in Alicante (Spain)
by: Ana C. Montagud, et al.
Published: (2025-01-01)

Trans amplifying mRNA vaccine expressing consensus spike elicits broad neutralization of SARS CoV 2 variants
by: Abhinay Gontu, et al.
Published: (2025-06-01)

Long-Term Dynamics of SARS-CoV-2 Variant-Specific Neutralizing Antibodies Following mRNA Vaccination and Infection
by: Veronika Vaňová, et al.
Published: (2025-05-01)

SCB-2019 protein vaccine as heterologous booster of neutralizing activity against SARS-CoV-2 Omicron variants after immunization with other COVID-19 vaccines
by: Camilo C. Roa, et al.
Published: (2024-12-01)

Using surveillance data to evaluate the effectiveness of inactivated/mRNA COVID-19 vaccine boosters in preventing fatal outcomes among severe COVID-19 cases during the current ambit of SARS-CoV-2 XBB and JN.1 variant circulation
by: Eugene S. K. Lo, et al.
Published: (2025-05-01)

Isolation of infectious SARS-CoV-2 from urine of a COVID-19 patient
by: Jing Sun, et al.
Published: (2020-01-01)

Receptor Binding for the Entry Mechanisms of SARS-CoV-2: Insights from the Original Strain and Emerging Variants
by: Mohamed Mahdi, et al.
Published: (2025-05-01)

Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines
by: Canjie Chen, et al.
Published: (2024-12-01)

Immune evasion, infectivity, and membrane fusion of the SARS-CoV-2 JN.1 variant
by: Haijun Tang, et al.
Published: (2025-05-01)

An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters
by: Yanjun Zhang, et al.
Published: (2025-05-01)

Origins of SARS-CoV-2: Focusing on Science
by: Zheng-Li Shi, et al.
Published: (2021-04-01)

The persistence of SARS-CoV-2 neutralizing antibodies after COVID-19: A one-year observation. Is a SARS-CoV-2 vaccination booster dose necessary?
by: Adam Tworek, et al.
Published: (2023-03-01)

Immunogenicity of intranasal vaccine based on SARS-CoV-2 spike protein during primary and booster immunizations in mice
by: Huijie Yang, et al.
Published: (2024-12-01)

Spatiotemporal prevalence of COVID-19 and SARS-CoV-2 variants in Africa
by: Li-Ping Gao, et al.
Published: (2025-02-01)

Evaluation of broad-spectrum protection by novel mRNA vaccines against SARS-CoV-2 variants (Delta, Omicron-BA.5, XBB-EG.5) in the golden hamster model
by: Tong Yu, et al.
Published: (2025-05-01)

Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster dosesResearch in context
by: Annalisa Ciabattini, et al.
Published: (2025-03-01)

Maternal and Perinatal Outcomes of SARS-CoV-2 and Variants in Pregnancy
by: Qiaoli Feng, et al.
Published: (2023-04-01)

Safety and immunogenicity of PHH-1V booster against SARS-CoV-2 variants, including omicron subvariants: Results from a phase IIb open-label extension study
by: María Jesús López, et al.
Published: (2025-12-01)

Author Correction: An RBD-Fc mucosal vaccine provides variant-proof protection against SARS-CoV-2 in mice and hamsters
by: Yanjun Zhang, et al.
Published: (2025-07-01)